CD8A and neoplasm: Previous in vitro studies have demonstrated that blocking CD70+ leukemia and B cell lymphoma cell lines using ARGX-110 can inhibit the activation of Treg and facilitate the anti-tumor immunity exerted by CD8+ effector T cells (66).